Home/Tenax Therapeutics/Stuart Rich, MD

SR

Stuart Rich, MD

Chief Medical Officer

Tenax Therapeutics

Therapeutic Areas

Cardiovascular Pulmonary Hypertension

Tenax Therapeutics Pipeline

Drug	Indication	Phase
TNX-103 (oral levosimendan)	Pulmonary Hypertension due to Heart Failure with preserved Ejection Fraction (PH-HFpEF)	Phase 3

Leadership Team at Tenax Therapeutics

Christopher Giordano

President and Chief Executive Officer

View full Tenax Therapeutics profile